Heart stent maker's IPO opens today. Should you care?

What's happening with the Sahajanand Medical IPO?

Sahajanand Medical Technologies' IPO of Rs 475.48 crore opened October 15 and closes October 19. Day one saw 34% subscription, with retail investors at 40%. The entire issue is an offer for sale, so the promoters, not the company, receive the money. Grey market premium stands at Rs 41 over the Rs 344 cap, implying a Rs 385 listing price. Allotment is October 21, listing October 23.

Why is the IPO demand lukewarm despite strong profit growth?

Our read: the lukewarm demand reflects the OFS structure, not the business. Since the company receives none of the Rs 475.48 crore, investors see no new capital for growth. Also, 73.67% of purchases in FY25 were from abroad, a risk that outweighs the 175% PAT jump for many. The grey market premium of 12% still suggests a modest listing gain.

If the company gets no money, who exactly is selling and why now?

The offer is entirely an offer for sale, so the money goes to the selling shareholders, not the company. The anchor investors paid Rs 344 per share, locking them in for 30 days from allotment, which signals institutions see some short-term value. The promoters are cashing out a partial stake while the business shows strong profit growth and expanding international approvals, like the recent Canadian license. Our read: this is the promoters monetising their holding at a favourable moment, not raising capital for growth.

If the company gets no money, what do the promoters gain from selling now?

The promoters are monetising their stake while the business still tells a strong story. FY26 profit jumped 175% to Rs 69 crore, the Canadian license for Supraflex Cruz just came through, and the company holds about 25% of India's DES market. The anchor investors paid Rs 344, the top of the band, which confirms institutions still see value at this price. Our read: the promoters are selling into the strongest news flow the company has had, because that is when they get the best price per share.

Who are the promoters actually selling to in this IPO?

The anchor book was subscribed by eight institutional investors at Rs 344, the top of the price band, on October 14. Of the Rs 140 crore raised, five domestic mutual fund houses - Nippon Life India, DSP Mutual Fund, WhiteOak Capital, Invesco India and UTI AMC - took roughly Rs 104 crore through seven schemes. Allianz Global Investors, Tata AIA Life Insurance and Natixis International Funds made up the rest. These institutions lock in for 30 days from allotment, so they are committed holders for at least the first month of trading. Our read: the promoters sold the anchor portion to long-only domestic funds, not hot-money traders, which gives the listing some stability.

Why are mutual funds comfortable buying before retail?

Mutual funds are buying at the same Rs 344 price as everyone else, but with two advantages. They get a confirmed allocation before the issue opens, and they are locked in for only 30 days from allotment, after which they can sell freely. The five domestic fund houses took roughly Rs 104 crore of the Rs 140 crore anchor portion. Our read: they are making a short-term bet on listing gains, not a long-term commitment, since their holding period is just one month.

What happens to the shares after the 30-day lock-in expires?

After 30 days from allotment, the anchor investors can sell their shares freely, and there is no restriction on them doing so. The lock-in applies only to the anchor portion, not to shares sold to retail or other investors. This means the mutual funds that took roughly Rs 104 crore of the Rs 140 crore anchor portion could exit as soon as late November, potentially adding selling pressure. Our read: the listing price at the end of November will depend heavily on whether these funds choose to cash out or hold for the long term.

What keeps the promoters from dumping shares right after listing?

SEBI rules lock the promoters' minimum contribution of 20% of post-issue capital for three years from allotment, and any shares held beyond that minimum are locked for one year. The promoters cannot sell or transfer these shares during the lock-in, except that the one-year locked shares can be pledged to banks as loan collateral. This means the promoters' stake stays intact for at least a year, and the three-year portion for three years, so they cannot exit alongside the anchor investors next month.

How does a small Indian stent maker compete with global giants?

Sahajanand holds about 25% of India's market for DES stents (drug-eluting stents, which slowly release medication to keep arteries open) and is among the top five in Germany, Spain, Poland and Brazil. It competes on price, offering stents 20-30% cheaper than established players, and on clinical evidence, its Supraflex Cruz showed non-inferiority in trials. The Canadian license opens another market, but Abbott, Boston Scientific and Medtronic still hold over 90% globally.

How does an OFS IPO work if the company gets no money?

In an offer for sale (OFS) IPO, the company does not issue new shares. Instead, existing shareholders, like the promoters, sell their own shares to the public. All the money raised, here, the Rs 475.48 crore from 1.38 crore shares, goes directly to those sellers. The company receives none of the proceeds but gains a stock market listing, which brings visibility and a valuation for future fundraising.

How can a small Indian company take on global giants in hospitals abroad?

Sahajanand already has a toehold in Europe and Brazil, ranking among the top five DES sellers in Germany, Spain, Poland and Brazil on sales volume. Its lever is price, undercutting established players by 20-30%, backed by clinical evidence from trials like TUXEDO-2 that show its stent is not worse than rivals'. The Canadian license adds a new market but a tiny one. Our read: the path is winning cost-sensitive public health systems in emerging regions, not denting Abbott, Boston Scientific and Medtronic's 90% global hold anytime soon.

Why are investors confident enough to anchor despite the weak retail demand?

The anchor book was sized at Rs 140 crore, or roughly 30% of the entire Rs 475.48 crore issue, and was filled at the top price band of Rs 344 per share. Five domestic mutual funds took Rs 104 crore of that allocation, with the rest going to foreign institutions like Allianz and Tata AIA. The lock-in is short: anchors can sell just 30 days after allotment. Our read: these institutions are betting on a quick listing gain over one month, not on the company's long-term prospects.

What actually happens to the shares once the lock-in ends?

After the anchor investors' 30-day lock-in expires, they are free to sell on the stock exchange, which can pressure the share price if many sell at once. The promoters face a longer restriction: SEBI rules lock in their minimum 20% contribution for three years from allotment, and these shares cannot be pledged during that period except for specific loan purposes. The remaining promoter shares have a one-year lock-in. Our read: the real test of demand comes after the anchors exit, not at listing.

What happens when promoters finally sell their stake?

The 20% promoter contribution is locked for three years from allotment and cannot be pledged except for loans tied to the issue's stated objects. The remaining promoter shares face a one-year lock-in. Selling such a large stake gradually or in blocks after lock-in can pressure the share price, but the sellers control the timing. Our read: any future large stake sale will be done through block deals or open market placements to avoid crashing the stock, and the market will watch those moves closely.

Why are global giants still dominant despite cheaper Indian rivals?

Regulatory approval, clinical evidence and hospital relationships create the moat. Stents are Class III devices requiring years of testing before commercialization, and established players like Abbott, Boston Scientific and Medtronic hold over 90% of the global DES market, according to the prospectus. SMT fights back with 20-30% lower prices and trials like TUXEDO-2, but only in select geographies. Our read: winning cost-sensitive public systems is possible, but displacing incumbents in wealthy markets is a decade-long battle, not an IPO story.

Why would Sahajanand do an OFS IPO?

Sahajanand's promoters are selling part of their stake in an offer-for-sale: the company issues no new shares, so the Rs 475.48 crore raised goes to them, not the business. In return, Sahajanand gets a public listing, giving it visibility, a market valuation, and a currency for future fundraising, acquisitions, or employee incentives.

Who benefits if the shares list above the IPO price?

If the shares list above the Rs 344 upper price band, the selling promoters gain most, since they pocket the entire Rs 475.48 crore from the offer-for-sale. Anchor investors, who paid Rs 344 per share, also stand to profit if they sell after their 30-day lock-in ends. The company itself receives nothing from the listing gain, as it issues no new shares. Our read: a strong listing rewards the sellers and early institutional backers, not the business or its future projects.